Clinical Trial Update: ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer [EARLY_Phase 1]

View source ↗

Summary

An EARLY Phase 1 trial of ERB-B4 following histone deacetylase inhibitor treatment in ER-positive, tamoxifen-refractory breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERB-B4

Snippet

Sponsor: Tulane University Health Sciences Center | Conditions: Breast Cancer | EARLY_Phase 1 | Status: WITHDRAWN